AbbVie’s stock took a hit after a lackluster third-quarter earnings report, causing a 4% drop in price. Despite a 9% revenue increase to $15.78 billion, profits fell below analyst estimates. CEO Robert Michael highlighted positive portfolio momentum. Adjusted net income guidance for 2025 was raised, but lower than analyst expectations.

Investors expressed disappointment in AbbVie’s earnings report, leading to a decline in stock price. Revenue increased by 9% to $15.78 billion, driven by popular drugs like Skyrizi and Rinvoq. Net income reached $3.3 billion, up from $2.3 billion in the same quarter last year. Adjusted net income guidance for 2025 was raised to $10.61 to $10.65 per share.

AbbVie’s earnings release highlighted growth in key portfolio areas and ongoing innovation investments. Despite the revenue and net income beating analyst estimates, adjusted net income guidance for 2025 fell below expectations. CEO Robert Michael emphasized the company’s progress and momentum in various sectors.

AbbVie’s stock faced a decline after the release of its third-quarter earnings report, causing investors to sell off shares. Despite positive revenue and net income figures, adjusted net income guidance for 2025 was lower than analyst estimates. CEO Robert Michael highlighted the company’s portfolio momentum and innovation efforts.

AbbVie’s stock performance faltered after releasing its third-quarter earnings report, resulting in a 4% drop in price. Despite revenue growth and increased net income, adjusted net income guidance for 2025 fell below analyst expectations. CEO Robert Michael emphasized the company’s positive portfolio momentum and innovation initiatives.

Read more at Yahoo Finance: Why AbbVie Stock Flopped on Friday